Gerthoffer William T
Department of Pharmacology, University of Nevada School of Medicine, Reno, NV 89557, USA.
Circ Res. 2007 Mar 16;100(5):607-21. doi: 10.1161/01.RES.0000258492.96097.47.
Smooth muscle cell migration occurs during vascular development, in response to vascular injury, and during atherogenesis. Many proximal signals and signal transduction pathways activated during migration have been identified, as well as components of the cellular machinery that affect cell movement. In this review, a summary of promigratory and antimigratory molecules belonging to diverse chemical and functional families is presented, along with a summary of key signaling events mediating migration. Extracellular molecules that modulate migration include small biogenic amines, peptide growth factors, cytokines, extracellular matrix components, and drugs used in cardiovascular medicine. Promigratory stimuli activate signal transduction cascades that trigger remodeling of the cytoskeleton, change the adhesiveness of the cell to the matrix, and activate motor proteins. This review focuses on the signaling pathways and effector proteins regulated by promigratory and antimigratory molecules. Prominent pathways include phosphatidylinositol 3-kinases, calcium-dependent protein kinases, Rho-activated protein kinase, p21-activated protein kinases, LIM kinase, and mitogen-activated protein kinases. Important downstream targets include myosin II motors, actin capping and severing proteins, formins, profilin, cofilin, and the actin-related protein-2/3 complex. Actin filament remodeling, focal contact remodeling, and molecular motors are coordinated to cause cells to migrate along gradients of chemical cues, matrix adhesiveness, or matrix stiffness. The result is recruitment of cells to areas where the vessel wall is being remodeled. Vessel wall remodeling can be antagonized by common cardiovascular drugs that act in part by inhibiting vascular smooth muscle cell migration. Several therapeutically important drugs act by inhibiting cell cycle progression, which may reduce the population of migrating cells.
平滑肌细胞迁移发生在血管发育过程中、对血管损伤的反应中以及动脉粥样硬化形成过程中。在迁移过程中激活的许多近端信号和信号转导途径已被确定,以及影响细胞运动的细胞机制的组成部分。在这篇综述中,介绍了属于不同化学和功能家族的促迁移和抗迁移分子的总结,以及介导迁移的关键信号事件的总结。调节迁移的细胞外分子包括小生物胺、肽生长因子、细胞因子、细胞外基质成分和心血管医学中使用的药物。促迁移刺激激活信号转导级联反应,触发细胞骨架重塑,改变细胞与基质的粘附性,并激活运动蛋白。这篇综述重点关注由促迁移和抗迁移分子调节的信号通路和效应蛋白。突出的途径包括磷脂酰肌醇3激酶、钙依赖性蛋白激酶、Rho激活的蛋白激酶、p21激活的蛋白激酶、LIM激酶和丝裂原激活的蛋白激酶。重要的下游靶点包括肌球蛋白II运动蛋白、肌动蛋白封端和切断蛋白、formin、原肌球蛋白、丝切蛋白和肌动蛋白相关蛋白2/3复合体。肌动蛋白丝重塑、粘着斑重塑和分子马达相互协调,使细胞沿着化学信号、基质粘附性或基质硬度梯度迁移。结果是细胞被招募到血管壁正在重塑的区域。血管壁重塑可以被常见的心血管药物拮抗,这些药物部分通过抑制血管平滑肌细胞迁移起作用。几种具有治疗重要性的药物通过抑制细胞周期进程起作用,这可能会减少迁移细胞的数量。